Sign in to view content

36-Month Outcomes of Injectable Fluocinolone Acetonide Intravitreal Insert on Recurrences of Non-infectious Posterior Segment Uveitis

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2019

Quan Dong Nguyen, MD, MSc

Late Breakers Symposium

Related

2 Real-World Analyses of Treatment Burden Associated With Intravitreal Injections for DME Prior to 0.2 mcg/Day Fluocinolone Acetonide (FAc)
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2018
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema
Raj K. Maturi, MD
Annual Meeting Talks
2018
Protocol U: Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involv
Raj K. Maturi, MD
Updates from the Field
2017

Category: Inflammatory and Infectious Diseases

Steroids

See more